The primary goals were to lower blood sugar levels and reduce the risk of diabetes-related complications
As of the October 2024 multisociety guidance led by the American Society of Anesthesiologists, the decision to stop Zepbound (tirzepatide) before surgery is individualized rather than automatic
Sourcing & Quality Assurance Quality assurance matters when buying research-use peptides like TB-500
For example, in the STEP UP Diabetes trial, participants taking 7.2 mg of semaglutide weekly lost an average of 13.2% of their initial weight, compared to 10.4% for those on the standard 2.4 mg weekly dose
In the 2026 ADA Scientific Sessions, results from the Phase-3 TRANSCEND-T2D-1 study involving retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, showed up to a 2% decrease in A1C and a 16.8% decrease in body weight over 40 weeks in patients with type 2 diabetes